Key Observations from Phase 2 Data Dose escalation reduced adverse events: Groups that used gradual dose titration reported fewer GI events than those starting at the target dose directly No deaths were attributed to the study drug Serious adverse events were reported at low rates across all groups, with no clear dose-dependent pattern for serious events The placebo group also reported substantial adverse events (72.1%), which is typical for trials of this size and duration TRIUMPH Phase 3 Adverse Event Profiles The TRIUMPH program consists of eight Phase 3 trials evaluating retatrutide across multiple indications including obesity, type 2 diabetes, and metabolic-associated steatotic liver disease (MASLD)
Can you take Zofran with other nausea meds
AOD-9604 was created to be: Safe Non-habit forming Non-stimulating Suitable for long-term metabolic support Cycling contradicts its original design
But buried in the legislation is something more consequential: mandatory safety data submission for self-affirmed GRAS ingredients
Wang, X., Wang, Q., Liu, Z., & Zheng, X